Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PVS1_Moderate
The NM_007194.4(CHEK2):c.593-1_594delGTTinsCTC(p.199) variant causes a splice acceptor, splice region, synonymous, intron change. The variant was absent in control chromosomes in GnomAD project. It is difficult to determine the true allele frequency of this variant because it is of type MNV, and the frequency of such variant types in population databases may be underestimated and unreliable. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. Synonymous variant affecting the same amino acid position (i.e. V198V) has been classified as Likely benign.
CHEK2 (HGNC:16627): (checkpoint kinase 2) In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
CHEK2 Gene-Disease associations (from GenCC):
CHEK2-related cancer predisposition
Inheritance: AD Classification: DEFINITIVE Submitted by: Ambry Genetics, ClinGen
Li-Fraumeni syndrome 2
Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
hereditary breast carcinoma
Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
acute myeloid leukemia
Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.055759802 fraction of the gene. Cryptic splice site detected, with MaxEntScore 7, offset of 27, new splice context is: cttttttgatctgactgtAGatg. Cryptic site results in inframe change. If cryptic site found is not functional and variant results in exon loss, it results in frameshift change.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_007194.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
Sel.
Gene
Transcript
Tags
HGVSc
HGVSp
Effect
Exon Rank
Protein
UniProt
CHEK2
NM_007194.4
MANE Select
c.593-1_594delGTTinsCTC
p.199
splice_acceptor splice_region synonymous intron
N/A
NP_009125.1
O96017-1
CHEK2
NM_001257387.3
c.-71-1_-70delGTTinsCTC
splice_region
Exon 6 of 16
NP_001244316.1
CHEK2
NM_001437942.1
c.-71-1_-70delGTTinsCTC
splice_region
Exon 4 of 14
NP_001424871.1
Ensembl Transcripts
Sel.
Gene
Transcript
Tags
HGVSc
HGVSp
Effect
Exon Rank
Protein
UniProt
CHEK2
ENST00000404276.6
TSL:1 MANE Select
c.593-1_594delGTTinsCTC
p.199
splice_acceptor splice_region synonymous intron
N/A
ENSP00000385747.1
O96017-1
CHEK2
ENST00000382580.6
TSL:1
c.722-1_723delGTTinsCTC
p.242
splice_acceptor splice_region synonymous intron
N/A
ENSP00000372023.2
O96017-9
CHEK2
ENST00000402731.6
TSL:1
c.482+5400_482+5402delGTTinsCTC
intron
N/A
ENSP00000384835.2
A0A7P0MUT5
Frequencies
GnomAD3 genomes
Cov.:
32
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.